Key facts
- Indapta Therapeutics’s last known valuation is $90.0M (May 2023).
- It has raised $162.3M across 4 recorded rounds; the latest was Later Stage VC ($50.8M) in Sep 2025.
- Notable investors include RA Capital Management, Cancer Prevention and Research Institute of Texas, Leaps by Bayer, Leerink Partners, Lonza Group — 11 tracked in total.
- Indapta Therapeutics has filed 1 Form D with the SEC, most recently Feb 2022 ($33.6M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Indapta Therapeutics
Funding rounds
4 roundsAbout Indapta Therapeutics
Operator of a biotechnology company focused on developing a natural killer cell therapy with potent activity to treat cancer. The company specializes in commercializing a proprietary off-the-shelf, non-engineered, and allogeneic cell to boost the immune response and substantially improve the cytotoxicity of antibody therapy, enabling healthcare providers to treat patients suffering from cancer.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2017
- Employees
- 14
- Website
- indapta.com/
- Ownership
- Privately Held (backing)
Indapta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Indapta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Indapta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.